Chicago / Edinburgh
Hong Kong · Hong Kong Stock Exchange

Sinotau Pharmaceutical

Sinotau Pharmaceutical develops, manufactures and sells diagnostic and therapeutic radiopharmaceuticals for detecting and treating diseases.

Sinotau Pharmaceutical (Ticker: 9941 HK) is a pharmaceutical company that develops, manufactures and sells diagnostic and therapeutic radiopharmaceuticals, which are medicines containing radioactive material used to help detect or treat disease. Its lead experimental candidate, XTR008, is a radioactive-labelled medicine designed to bind to somatostatin receptors on neuroendocrine tumour cells. The company reports 13 assets in its pipeline as of October 21, 2026. Founded in 2005, Sinotau has manufacturing sites in Wuxi, Zhongshan and Mianyang, and reported revenue of RMB 99.00 million for 2025.

The company is expected to begin trading on Hong Kong Stock Exchange on November 24, 2026. The IPO comprises 6,561,000 base shares, with an indicative offer price range of HKD 52.00 to HKD 68.00 per share. At the HKD 60.00 midpoint, the base offering would represent approximately HKD 393.66 million in gross proceeds, equivalent to approximately $50.22 million. The price determination date is November 20, 2026.

Estimated IPO market capitalization is HKD 3.94 billion, or approximately $501.98 million. GF Capital (Hong Kong) Limited, China International Capital Corporation Hong Kong Securities Limited and CITIC Securities (Hong Kong) Limited serve as joint sponsors of the IPO.

Prepared with IPOX® AI assistance. Information may contain errors.

Prepared with IPOX® AI assistance. Information may contain errors.

THE IPOX® NEWSLETTERS

Stay ahead of the next listing.

Research and insight from the global new listings market.

Explore our newsletters